CN102526371A - Medicine for inflammation diminishing, pain stopping, blood activating and detumescence for veterinary use and preparation method thereof - Google Patents
Medicine for inflammation diminishing, pain stopping, blood activating and detumescence for veterinary use and preparation method thereof Download PDFInfo
- Publication number
- CN102526371A CN102526371A CN2012100801000A CN201210080100A CN102526371A CN 102526371 A CN102526371 A CN 102526371A CN 2012100801000 A CN2012100801000 A CN 2012100801000A CN 201210080100 A CN201210080100 A CN 201210080100A CN 102526371 A CN102526371 A CN 102526371A
- Authority
- CN
- China
- Prior art keywords
- pain
- grams
- preparation
- detumescence
- analgesic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 22
- 229940079593 drug Drugs 0.000 title claims abstract description 13
- 238000002360 preparation method Methods 0.000 title claims abstract description 11
- 208000002193 Pain Diseases 0.000 title description 28
- 230000036407 pain Effects 0.000 title description 28
- 206010061218 Inflammation Diseases 0.000 title description 11
- 230000004054 inflammatory process Effects 0.000 title description 10
- 239000008280 blood Substances 0.000 title description 9
- 210000004369 blood Anatomy 0.000 title description 9
- 230000003213 activating effect Effects 0.000 title 1
- 230000003467 diminishing effect Effects 0.000 title 1
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims abstract description 14
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 claims abstract description 14
- 229940116229 borneol Drugs 0.000 claims abstract description 14
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 claims abstract description 14
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 claims abstract description 14
- 230000000202 analgesic effect Effects 0.000 claims abstract description 13
- 230000017531 blood circulation Effects 0.000 claims abstract description 12
- 235000015655 Crocus sativus Nutrition 0.000 claims abstract description 11
- 244000124209 Crocus sativus Species 0.000 claims abstract description 11
- 230000003110 anti-inflammatory effect Effects 0.000 claims abstract description 11
- 235000013974 saffron Nutrition 0.000 claims abstract description 11
- 239000004248 saffron Substances 0.000 claims abstract description 11
- 241000758794 Asarum Species 0.000 claims abstract description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 9
- 239000000443 aerosol Substances 0.000 claims abstract description 8
- 239000002994 raw material Substances 0.000 claims abstract description 3
- 239000000273 veterinary drug Substances 0.000 claims abstract description 3
- 230000000694 effects Effects 0.000 abstract description 12
- 238000001914 filtration Methods 0.000 abstract 1
- 238000002386 leaching Methods 0.000 abstract 1
- 231100000331 toxic Toxicity 0.000 abstract 1
- 230000002588 toxic effect Effects 0.000 abstract 1
- 230000008961 swelling Effects 0.000 description 10
- 230000001737 promoting effect Effects 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 230000000144 pharmacologic effect Effects 0.000 description 5
- 230000000844 anti-bacterial effect Effects 0.000 description 4
- 230000008506 pathogenesis Effects 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 206010042674 Swelling Diseases 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000004064 dysfunction Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 208000006820 Arthralgia Diseases 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- 206010068319 Oropharyngeal pain Diseases 0.000 description 2
- 201000007100 Pharyngitis Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 229940124350 antibacterial drug Drugs 0.000 description 2
- 239000003181 biological factor Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 208000014617 hemorrhoid Diseases 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 210000002435 tendon Anatomy 0.000 description 2
- 208000004371 toothache Diseases 0.000 description 2
- 239000000341 volatile oil Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 241000304886 Bacilli Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 206010006002 Bone pain Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 206010058019 Cancer Pain Diseases 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 241000498255 Enterobius vermicularis Species 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 241000475481 Nebula Species 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 206010033078 Otitis media Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 241000606701 Rickettsia Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000589970 Spirochaetales Species 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000001518 anti-nephritic effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 230000003260 anti-sepsis Effects 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- VEQOALNAAJBPNY-UHFFFAOYSA-N antipyrine Chemical compound CN1C(C)=CC(=O)N1C1=CC=CC=C1 VEQOALNAAJBPNY-UHFFFAOYSA-N 0.000 description 1
- 208000002399 aphthous stomatitis Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 125000002604 borneol group Chemical group 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 208000027744 congestion Diseases 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 231100000895 deafness Toxicity 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000004665 defense response Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 206010014881 enterobiasis Diseases 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 208000016354 hearing loss disease Diseases 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000009416 jing wan hong Substances 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000000941 radioactive substance Substances 0.000 description 1
- 210000001927 retinal artery Anatomy 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 201000009890 sinusitis Diseases 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 229940098465 tincture Drugs 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 1
- 229960005294 triamcinolone Drugs 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 239000009291 xinhuang Substances 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种兽用消炎止痛活血消肿药物及其制备方法,所述药物由以下原料药组成:藏红花1-4克,细辛2-7克,冰片7-15克。其制备方法是将上述原料药浸于1000毫升85%乙醇72小时,浸出液过滤装瓶制成气雾剂。本发明方便快捷,疗效显著,且无毒副作用,其平均治愈率达91%及以上。The invention discloses a veterinary drug for anti-inflammatory, analgesic, blood circulation and detumescence and a preparation method thereof. The drug is composed of the following raw materials: 1-4 grams of saffron, 2-7 grams of asarum and 7-15 grams of borneol. The preparation method is as follows: immersing the above crude drug in 1000 milliliters of 85% ethanol for 72 hours, filtering and bottling the leaching solution to prepare the aerosol. The invention is convenient and quick, has remarkable curative effect, and has no toxic and side effects, and its average cure rate reaches 91% and above.
Description
[技术领域] [technical field]
本发明涉及兽用中药,尤其涉及一种治疗大型动物牛马、小型动物猪羊以及宠物犬猫等外科炎肿疼痛的药物。The invention relates to veterinary traditional Chinese medicine, in particular to a medicine for treating surgical inflammation and pain of large animals such as cattle and horses, small animals such as pigs and sheep, and pet dogs and cats.
[背景技术] [Background technique]
外科炎肿疼痛是临床一个大的类别疾病,可以发生于动物身体的各个部位,也可以发生于周身各个组织,尤其发生于皮肤、皮下结缔组织、肌腱和韧带、骨和软骨等组织。外科炎肿疼痛是机体对于刺激的一种防御反应,表现为红、肿、热、痛和功能障碍。生物性因子如细菌、病毒、立克次体、支原体、真菌、螺旋体和寄生虫等为炎症肿涨疼痛最常见的原因。物理性因子如高温、低温、放射性物质及紫外线等和机械损伤。化学性因子如外源性化学物质如强酸、强碱等都可以造成。所以该现象广泛见于临床,尤其在小动物(犬猫)临床中多见。西医在治疗该症状主要采取和用激素药物抑制免疫。抗菌药物抑制细菌毒性和副作用大且会造成抗药性。抗菌药物针对性强,仅仅适用于生物性因子如某些细菌感染造成的炎症肿涨疼痛,机能障碍,对于物理性因子、化学性因子等非感染性的炎症肿涨疼痛,机能障碍就未见其功。激素药物副作用大,对机体负面影响深。会造成浮肿、糖尿、骨质疏松、较易导致胃粘膜损伤,诱发溃疡等。Surgical inflammation and pain is a large category of clinical diseases, which can occur in various parts of the animal body, and can also occur in various tissues around the body, especially in skin, subcutaneous connective tissue, tendon and ligament, bone and cartilage and other tissues. Surgical inflammation and pain is a defense response of the body to stimulation, manifested as redness, swelling, heat, pain and dysfunction. Biological factors such as bacteria, viruses, rickettsia, mycoplasma, fungi, spirochetes and parasites are the most common causes of inflammation, swelling and pain. Physical factors such as high temperature, low temperature, radioactive substances and ultraviolet rays, and mechanical damage. Chemical factors such as exogenous chemical substances such as strong acid and strong alkali can cause it. Therefore, this phenomenon is widely seen in clinics, especially in small animals (dogs and cats). Western medicine mainly adopts and suppresses immunity with hormone drugs in the treatment of this symptom. Antibacterial drugs inhibit bacterial toxicity and side effects and can cause drug resistance. Antibacterial drugs are highly targeted, and are only suitable for inflammation, swelling, pain, and dysfunction caused by biological factors such as certain bacterial infections. For non-infectious inflammation, swelling, pain, and dysfunction caused by physical factors, chemical factors, etc. Its merit. Hormone drugs have large side effects and have a deep negative impact on the body. It can cause edema, diabetes, osteoporosis, easily cause gastric mucosal damage, and induce ulcers.
[发明内容] [Content of the invention]
本发明要解决的技术问题是提供一种兽用消炎止痛活血消肿药物。The technical problem to be solved by the present invention is to provide a veterinary drug for anti-inflammatory, analgesic, blood circulation and detumescence.
本发明要解决的另外一个技术问题是提供一种兽用消炎止痛活血消肿气雾剂的制备方法。Another technical problem to be solved by the present invention is to provide a preparation method of an aerosol for veterinary anti-inflammation, analgesia, promoting blood circulation and detumescence.
对于兽用消炎止痛活血消肿药物,本发明采用的技术方案是,一种兽用消炎止痛活血消肿药物,由以下原料药组成:藏红花1-4克,细辛2-7克,冰片7-15克。For veterinary medicines for anti-inflammatory, analgesic, blood circulation and detumescence, the technical solution adopted in the present invention is a veterinary medicine for anti-inflammatory, analgesic, blood circulation and detumescence, which consists of the following raw materials: 1-4 grams of saffron, 2-7 grams of asarum, 7 grams of borneol -15 grams.
对于兽用消炎止痛活血消肿气雾剂的制备方法,本发明采用的技术方案是,制备方法如下:将上述原料药浸于1000毫升85%乙醇72小时,浸出液过滤后装瓶制成气雾剂。For the preparation method of veterinary anti-inflammatory, analgesic, blood circulation and detumescence aerosol, the technical scheme adopted by the present invention is that the preparation method is as follows: soak the above-mentioned crude drug in 1000 ml of 85% ethanol for 72 hours, filter the leachate and bottle it to make aerosol agent.
本发明的解决方案基于动物外科外科炎肿疼痛的发病机理以及中兽医学的治疗原则,参考现代中药药理学研究选用活血祛瘀、祛风止痛、消肿防腐药物构成。可以抑菌,止疼,祛瘀,生新,从而达到解决外科外科炎肿疼痛之目的。The solution of the present invention is based on the pathogenesis of inflammation and pain in animal surgery and the treatment principles of traditional Chinese veterinary medicine. With reference to the pharmacological research of modern Chinese medicine, it is composed of drugs for promoting blood circulation and removing blood stasis, dispelling wind and relieving pain, and reducing swelling and antisepsis. It can inhibit bacteria, relieve pain, remove blood stasis, and regenerate, so as to achieve the purpose of solving surgical inflammation and pain.
本发明药物机理如下:Drug mechanism of the present invention is as follows:
藏红花平性味甘,无毒体轻质润,入血行散具有活血祛瘀,散郁开结,凉血解毒的功效。主治产后瘀血腹痛,跌扑肿痛。现代药理学研究发现,藏红花可对氧自由基有抑制作用,从而达到抗氧化的作用;藏红花还有兴奋子宫、活血止血、抗肾炎、促进视网膜动脉血流量等功能。现代药理学研究发现Saffron is flat in nature and sweet in taste, non-toxic, light in weight and moist in body. Ruxue Xingsan has the effects of promoting blood circulation and dispelling blood stasis, dispelling stagnation and opening knots, cooling blood and detoxifying. Cure mainly postpartum blood stasis abdominal pain, tumbling and swelling. Modern pharmacological studies have found that saffron can inhibit oxygen free radicals, thereby achieving anti-oxidation; saffron also has the functions of stimulating the uterus, promoting blood circulation and stopping bleeding, anti-nephritis, and promoting blood flow in retinal arteries. Modern pharmacological research has discovered
细辛味辛,温祛风,散寒。功能主治:行水,开窍。治风冷头痛,鼻渊,齿痛,痰饮咳逆,风湿痹痛。现代药理学研究发现:细辛具有解热镇痛局麻镇静;其挥发油对家兔有镇痛作用,其镇痛强度与安替匹林0.5mg/kg相当。水煎剂灌胃对小鼠也有镇痛作用。此外还具有抗炎免疫抑制和抗变态反应;抗菌作用:醇浸剂、挥发油等对多种革兰阳性菌、多种杆菌和多种真菌有抑制作用。Herba Asari is pungent in the mouth, warms and dispels wind, dispels cold. Functions and indications: running water, resuscitating. Control wind-cold headache, nasal sinusitis, toothache, phlegm retention and cough, rheumatic arthralgia. Modern pharmacological studies have found that Asarum has antipyretic, analgesic and local anesthetic sedative properties; its volatile oil has analgesic effects on rabbits, and its analgesic strength is equivalent to that of antipirin 0.5 mg/kg. Oral administration of water decoction also has an analgesic effect on mice. In addition, it also has anti-inflammatory, immunosuppressive and anti-allergic effects; antibacterial effect: alcohol infusions, volatile oils, etc. have inhibitory effects on various Gram-positive bacteria, various bacilli and various fungi.
冰片味辛、苦,性凉。功能:通诸窍、散郁火、去翳明目、消肿止痛。主治:中风口噤、热病神昏、惊痫痰迷、气闭耳聋、喉痹、口疮、中耳炎、痈肿、痔疮、目赤翳膜、蛲虫病。《纲目》:疗喉痹,脑痛,鼻息,齿痛;《会约医镜》:治肢节疼痛。《海药本草》:三虫,治五痔,李杲:治骨痛。现代药理学研究发现:抑菌、抗炎作用。体外实验表明:较高浓度的冰片(0.5%)有抑菌作用。合成冰片和天然冰片的抑菌作用相同。止痛作用:含冰片的复方制剂冰砂酊及冰星液加新癀片治疗癌症疼痛取得一定治疗效果。冰片对烧伤创面的镇痛及抗炎作用,实验结果表明使用冰片组的动物模型病阈值比京万红组(阳性对照)和生理盐水组(阴性对照组)分别高2.78倍和6.24倍。冰片还具有促进其他药物透皮吸收的作用,能促进曲安缩松透皮吸收。Borneolum is pungent in the mouth, bitter, cool in nature. Function: open all orifices, disperse stagnant fire, remove nebula and improve eyesight, reduce swelling and relieve pain. Indications: apoplexy, fever, coma, convulsions, epilepsy, phlegm confusion, air-occlusion deafness, sore throat, aphtha, otitis media, carbuncle, hemorrhoids, red eyes and film, pinworms. "Compendium": treat sore throat, brain pain, snort, toothache; "meeting medical mirror": treat joint pain. "Haiyao Materia Medica": three worms, five hemorrhoids, Li Gao: bone pain. Modern pharmacological research has found: antibacterial and anti-inflammatory effects. In vitro experiments showed that higher concentration of borneol (0.5%) has antibacterial effect. Synthetic borneol and natural borneol have the same antibacterial effect. Analgesic effect: The compound preparation Bingsha tincture containing borneol and Bingxing liquid plus Xinhuang tablet have achieved certain therapeutic effect in the treatment of cancer pain. The analgesic and anti-inflammatory effects of borneol on burn wounds, the experimental results show that the animal model disease threshold of the borneol group is 2.78 times and 6.24 times higher than that of Jingwanhong group (positive control) and normal saline group (negative control group). Borneol also has the effect of promoting the transdermal absorption of other drugs, and can promote the transdermal absorption of triamcinolone.
中兽医理论认为肿胀疼痛的产生机理主要筋脉不通,不通则痛如瘀血阻络,经络阻滞不痛则会造成疼痛。外寒、外风、外热、外湿、外伤、劳倦损伤均可引起肿胀疼痛。《内经》:“痛者寒气多也”,细辛味辛,温祛风,散寒就是解决其根本原因。在《内经》病因理论的基础上,金元时期的医学发明家李东恒,首次提出“痛则不通”的病机理论学说,并确立“痛随利减,当通其经络,则疼痛去矣”的以通止痛的原则。清代叶天土在《临证指南医案》中提出“久痛入络”之病机理论。王清任在《医林改错》、唐容川在《血证论》中均进一步阐述了淤血致痛之病机。藏红花、冰片活血祛瘀,通络散结。藏红花、冰片、细辛三味达到治疗肿胀痛疼之功效。Veterinary medicine theory of traditional Chinese medicine believes that the main mechanism of swelling and pain is blockage of tendons and vessels, which causes pain like blood stasis blocking collaterals, and blockage of meridians and collaterals causes pain if it is not painful. Exogenous cold, exogenous wind, exogenous heat, exogenous dampness, trauma, fatigue injury all can cause swelling and pain. "Internal Classics": "Pain sufferers with a lot of cold air", Asarum is pungent in taste, warming and expelling wind, and expelling cold is the root cause. On the basis of the theory of etiology in the "Internal Classics", Li Dongheng, a medical inventor in the Jin and Yuan dynasties, first proposed the theory of pathogenesis that "pain is unreasonable", and established that "pain decreases with benefit, and when the meridian is unblocked, the pain will go away." The principle of pain relief. In the Qing Dynasty, Ye Tiantu proposed the pathogenesis theory of "long-term pain entering the collaterals" in "Clinical Guide to Medical Cases". Wang Qingren's "Yilin Gaicuo" and Tang Rongchuan's "Blood Syndrome" further elaborated on the pathogenesis of congestion-induced pain. Saffron and Borneol promote blood circulation and remove blood stasis, dredge collaterals and dissipate stagnation. Saffron, borneol, and asarum three flavors achieve the effect of treating swelling and pain.
本发明的有益效果是:The beneficial effects of the present invention are:
作为一种纯中药气雾剂,对外科炎肿疼痛通过消炎、消肿、止痛达到恢复组织或器官的机能的目的,具有制作简单,使用便捷,见效快,疗效显著的特点,其平均治愈率达91%及以上。As a pure traditional Chinese medicine aerosol, it can restore the function of tissues or organs through anti-inflammatory, detumescence and pain relief for surgical inflammation and pain. It has the characteristics of simple production, convenient use, quick effect and remarkable curative effect. Its average cure rate Up to 91% and above.
[具体实施方式][Detailed ways]
以下结合3个实施例对本发明做进一步说明:The present invention will be further described below in conjunction with 3 embodiments:
实施例1:Example 1:
1、配方:藏红花1克;细辛2克;冰片7克。1. Formula: 1 gram of saffron; 2 grams of asarum; 7 grams of borneol.
2、制备方法:2. Preparation method:
(1)将上述粉碎成微粉(300目),药物微粉浸于1000毫升85%乙醇72小时,过滤。(1) Pulverize the above into fine powder (300 mesh), soak the drug fine powder in 1000 ml of 85% ethanol for 72 hours, and filter.
(2)将过滤液装瓶制成气雾剂。(2) Bottle the filtrate to make an aerosol.
3、治疗效果:本实施例疗效统计如表1所示。3. Therapeutic effect: The curative effect statistics of this embodiment are as shown in Table 1.
表1Table 1
如表1所示,909例的平均治愈率为91%。As shown in Table 1, the average cure rate of 909 cases was 91%.
实施例2:Example 2:
1、配方:藏红花2克;细辛5克;冰片11克。1. Formula: 2 grams of saffron; 5 grams of asarum; 11 grams of borneol.
2、制备方法:同实施例1。2, preparation method: with embodiment 1.
3、治疗效果:本实施例疗效统计如表2所示。3. Therapeutic effect: The curative effect statistics of this embodiment are as shown in Table 2.
表2:Table 2:
如表2所示,1913例的平均治愈率为96.4%。As shown in Table 2, the average cure rate of 1913 cases was 96.4%.
实施例3:Example 3:
1、配方:藏红花4克;细辛7克;冰片15克。1. Formula: 4 grams of saffron; 7 grams of asarum; 15 grams of borneol.
2、制备方法:同实施例1。2, preparation method: with embodiment 1.
3、治疗效果:本实施例疗效统计如表3所示。3. Therapeutic effect: The curative effect statistics of this embodiment are as shown in Table 3.
表3:table 3:
如表3所示,403例的平均治愈率为94.6%。As shown in Table 3, the average cure rate of 403 cases was 94.6%.
Claims (2)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2012100801000A CN102526371A (en) | 2012-03-16 | 2012-03-16 | Medicine for inflammation diminishing, pain stopping, blood activating and detumescence for veterinary use and preparation method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2012100801000A CN102526371A (en) | 2012-03-16 | 2012-03-16 | Medicine for inflammation diminishing, pain stopping, blood activating and detumescence for veterinary use and preparation method thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN102526371A true CN102526371A (en) | 2012-07-04 |
Family
ID=46335191
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2012100801000A Pending CN102526371A (en) | 2012-03-16 | 2012-03-16 | Medicine for inflammation diminishing, pain stopping, blood activating and detumescence for veterinary use and preparation method thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102526371A (en) |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0376024A (en) * | 1989-08-17 | 1991-04-02 | Fuji Photo Film Co Ltd | Production of magnetic recording medium |
JPH09176024A (en) * | 1995-12-27 | 1997-07-08 | Pigeon Corp | Childhood medicine |
CN1256134A (en) * | 1998-12-10 | 2000-06-14 | 徐光� | Powerful meridian passage dredging detoxication liquid |
CN1303706A (en) * | 1999-12-02 | 2001-07-18 | 白云杰尔 | Compound sweet wormwood Mongolian medicine insufflation |
WO2002058625A2 (en) * | 2000-12-22 | 2002-08-01 | Tianjin Tasly Pharmaceutical Co., Ltd., China | Herbal composition for angina pectoris, method to prepare same and uses thereof |
US20030003165A1 (en) * | 2001-06-14 | 2003-01-02 | Medvill Co., Ltd. | Hypertension-treatment composition containing panax notoginseng and salvia miltiorhiza and method of preparing same |
CN101347598A (en) * | 2007-07-22 | 2009-01-21 | 郭武军 | Liniment spray for bonesetting and pain-alleviating |
CN101843801A (en) * | 2010-04-30 | 2010-09-29 | 张龙振 | Bone permeable blood-activating and pain-relieving tincture |
CN102048780A (en) * | 2009-11-01 | 2011-05-11 | 王玉凤 | Plaster for treating toothache |
CN102210813A (en) * | 2011-05-31 | 2011-10-12 | 徐斯润 | Traditional Chinese medicine composition for diminishing inflammation and relieving toxicity for livestock and poultry and preparation method thereof |
-
2012
- 2012-03-16 CN CN2012100801000A patent/CN102526371A/en active Pending
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0376024A (en) * | 1989-08-17 | 1991-04-02 | Fuji Photo Film Co Ltd | Production of magnetic recording medium |
JPH09176024A (en) * | 1995-12-27 | 1997-07-08 | Pigeon Corp | Childhood medicine |
CN1256134A (en) * | 1998-12-10 | 2000-06-14 | 徐光� | Powerful meridian passage dredging detoxication liquid |
CN1303706A (en) * | 1999-12-02 | 2001-07-18 | 白云杰尔 | Compound sweet wormwood Mongolian medicine insufflation |
WO2002058625A2 (en) * | 2000-12-22 | 2002-08-01 | Tianjin Tasly Pharmaceutical Co., Ltd., China | Herbal composition for angina pectoris, method to prepare same and uses thereof |
US20030003165A1 (en) * | 2001-06-14 | 2003-01-02 | Medvill Co., Ltd. | Hypertension-treatment composition containing panax notoginseng and salvia miltiorhiza and method of preparing same |
CN101347598A (en) * | 2007-07-22 | 2009-01-21 | 郭武军 | Liniment spray for bonesetting and pain-alleviating |
CN102048780A (en) * | 2009-11-01 | 2011-05-11 | 王玉凤 | Plaster for treating toothache |
CN101843801A (en) * | 2010-04-30 | 2010-09-29 | 张龙振 | Bone permeable blood-activating and pain-relieving tincture |
CN102210813A (en) * | 2011-05-31 | 2011-10-12 | 徐斯润 | Traditional Chinese medicine composition for diminishing inflammation and relieving toxicity for livestock and poultry and preparation method thereof |
Non-Patent Citations (2)
Title |
---|
胡丽华: "败毒止痛酊治疗带状疱疹152 例", 《山东中医杂志》 * |
范全等: "中药熏洗疗法对断指再植术后患指屈曲功能的影响", 《中国中医骨伤科杂志》 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104352587B (en) | A kind of ointment for treating rhinitis | |
CN102526411B (en) | Chinese medicinal composition for treating surgical wound | |
CN103341154B (en) | Compound veterinary injection for clearing heat and removing toxin | |
CN111529592A (en) | Traditional Chinese medicine composition for preventing and treating hemorrhoids and preparation method thereof | |
CN102824449A (en) | External tincture with anti-inflammation detumescence and wound healing promotion functions | |
CN103251691B (en) | Chinese medicine formula for treating bovine mastitis as well as extract and preparation thereof | |
CN101843801A (en) | Bone permeable blood-activating and pain-relieving tincture | |
CN114177231B (en) | A kind of antipyretic pharmaceutical composition, antipyretic gel and preparation method | |
CN100444887C (en) | Application of composition for preparing medicine to treat chilblain disease | |
CN101322717A (en) | Medicament composition for preventing and treating eye diseases | |
CN104547825B (en) | A kind of preparation method for the Chinese medicine composition and its preparation for treating myoneural pain | |
CN102526371A (en) | Medicine for inflammation diminishing, pain stopping, blood activating and detumescence for veterinary use and preparation method thereof | |
CN101822693A (en) | Medicine treating tympanitis | |
CN105395527A (en) | A preparing method of a marine-organism wound-protecting film spraying agent | |
CN104740140B (en) | A kind of Chinese medicine external care drug treating burn and scald | |
CN100348239C (en) | Traditional Chinese medicine preparation for treating soft tissue pain and preparation method | |
CN101647954A (en) | Traditional Chinese medicine for treating cervicitis and preparation method and application thereof | |
CN107050395B (en) | Traditional Chinese medicine sigmoid colon drip preparation for treating exogenous fever in children and its preparation method and application | |
CN100560079C (en) | A kind of traditional Chinese medicine injection for treating hemorrhoids | |
CN1246367A (en) | Medicine for treating tinea | |
CN103285132B (en) | External preparation for treating skin wound | |
CN105193934B (en) | A kind of compound essential oil for treating domestic animal endometritis and preparation method thereof | |
CN117427109A (en) | Pain-relieving and inflammation-diminishing external traditional Chinese medicine preparation and preparation method thereof | |
CN117298188A (en) | Traditional Chinese medicine for treating rhinitis and preparation method thereof | |
CN103055290B (en) | Medicine for nasal cavity for curing nasitis and preparation method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20120704 |